The selling is routine in both dollar amount and as a fraction of market cap. Director Rhodes' sales are likely part of a pre-arranged 10b5-1 plan or portfolio diversification. No insider buying to suggest bullish conviction. Monitor for any material news (e.g., clinical trial updates) that could explain the selling, but the cluster alone does not warrant a bearish read.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $18.90entry
- T+1 · 7mo ago −3.39%α −4.16% · $18.26
- T+5 · 7mo ago −7.14%α −8.58% · $17.55
- T+20 · 6mo ago −8.10%α −12.93% · $17.37
- T+60 · 4mo ago +26.08%α +20.46% · $23.83
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Dyne Therapeutics directors sold a total of ~$1.15M in stock over a 7-day window, with Director Rhodes Jason P executing the bulk of the sales (~$2.6M across multiple trades). The selling represents ~0.04% of the company's $2.9B market cap, which is trivial and routine. No insider buying was reported, and the cluster is dominated by a single director's open-market sales.
Key Financial Metrics
Key Facts
- Total insider sales of ~$1.15M over 7 days, representing ~0.04% of $2.9B market cap
- Director Rhodes Jason P sold 142,924 shares for ~$2.6M across three trades (Apr 24-28)
- Director Kersten Dirk sold 2,700 shares for $53K on Apr 22
- Director Lubner David Charles gifted 53,625 shares (non-cash, $0 value) on Apr 24
- No open-market purchases by any insider in the cluster
- Prior 30-day insider activity shows 9 sells totaling $8.6M, consistent with ongoing selling pattern
Financial Impact
Total insider sales of ~$1.15M, or ~0.04% of market cap, immaterial
Risk Factors
- Continued insider selling pattern (9 sells / $8.6M in prior 30 days) could indicate lack of confidence if it accelerates
- No insider buying to counterbalance the selling signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1777584169350 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers